KRAS and non-small cell lung carcinoma: We demonstrated that AKT1 inhibition promoted migration and invasion of NSCLC cells with KRAS or EGFR mutation in vitro, and the pan-AKT inhibitor MK-2206 promoted A549 metastasis in vivo.